Cardiovascular Imaging in Patients with Chronic Kidney Disease

Cristina Karohl\textsuperscript{a, b} Paolo Raggi\textsuperscript{a}

\textsuperscript{a}Division of Cardiology and Department of Medicine, Emory University School of Medicine, Atlanta, Ga., USA; 
\textsuperscript{b}Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil


doi: 10.1159/000321839

Abstract
Cardiovascular disease is highly prevalent in chronic kidney disease and has been associated with increased morbidity and mortality. Several morphological and functional tests are available to assess the cardiovascular system. Since structural and functional cardiovascular abnormalities have prognostic implications, their identification may become crucial for the implementation of effective preventive and therapeutic strategies. We review the most frequently used imaging methods to investigate structural and functional cardiovascular changes in patients with chronic kidney disease.

Key Words
Cardiovascular imaging • Cardiovascular disease • Calcification • Chronic kidney disease

Introduction
In the recent past, the interest in cardiovascular disease complications in patients with chronic kidney disease (CKD) has greatly intensified. In fact, the cardiovascular morbidity and mortality of these patients is a magnitude greater than that of the general population [1]. Besides traditional factors, CKD patients are exposed to unique risk factors, such as altered mineral metabolism, enhanced oxidative stress and inflammation, volume and pressure overload. Several CKD patients develop a form of uremic cardiomyopathy that results both in systolic and diastolic ventricular dysfunction. Valvular calcification and vascular calcification (VC), known to be extensive in CKD and believed to be secondary to a combination of accelerated atherosclerosis and altered mineral metabolism, likely contribute to the development of uremic cardiomyopathy. In this disease state, extensive intramyocardial fibrosis may predispose to reentry arrhythmias and sudden death [2].

As the presence of cardiovascular abnormalities has prognostic and therapeutic implications, their identification may become crucial for the implementation of effective preventive and therapeutic strategies. In this review, we will discuss the utilization of imaging methods to investigate structural as well as functional changes of the cardiovascular system in patients with CKD.

Structural Imaging Tests
Several methods are available to investigate structural cardiovascular changes: planar X-rays, computed tomography (CT), cardiac magnetic resonance (CMR), echocardiography, and ultrasound (US).
Planar X-Ray

Single-plane (planar) radiography is a simple, widely available and inexpensive tool that can be used to evaluate the presence of VC (fig. 1). Although mostly qualitative, several semiquantitative methods have been developed. The best known is the one originally proposed by Kaupila et al. [3] whereby calcification of the abdominal aorta (AAC), visualized on a lateral X-ray of the lumbar spine, is given a score of 0–24 based on the number and extent of calcified foci in the aortic segments extending in front of lumbar vertebrae 1–4. Other methods include the simple VC score (SVCS) proposed by Adragão et al. [4], and plane X-rays of the pelvis and thigh for ileofemoral calcification [5].

The SVCS was used in an observational study of 123 hemodialysis patients followed for a mean of 37 months. The presence of calcification in the femoral, iliac, radial, and digital arteries was scored from 0 (no visible calcification) to 8 (all vessels calcified). Some degree of VC was detected in 75% of the study patients, and more than half of them had a score ≥3. During 37 months of follow-up, the SCVS was associated with higher risk of cardiovascular events, hospitalization and death (hazard risk, HR, for score ≥3: 3.9; 95% CI 1.1–13.4; p = 0.03) [4].

The AAC score was initially described for quantification of VC in a subgroup of 617 Framingham Heart Study participants. The AAC score was shown to be predictive of cardiovascular events and mortality in two cohorts of the Framingham Heart Study [6, 7]. In an observational study of 515 maintenance hemodialysis patients, Okuno et al. [8] showed that the AAC score was predictive of all-cause mortality (HR 2.07; 95% CI 1.21–3.56; p < 0.05) and cardiovascular mortality (HR 2.39; 95% CI 1.01–5.66; p < 0.05) after adjustment for age, hemodialysis duration, diabetes mellitus, serum albumin level, and C-reactive protein level.

No study has yet evaluated the use of the SVCS and the AAC score in patients with early CKD. The qualitative nature of planar radiography limits its applicability to sequential imaging. The ongoing multicenter study CORD (Calcification Outcome in Renal Disease), a European observational study of dialysis patients, might answer some of these questions in the near future [9].

Computed Tomography

Electron beam CT (EBCT) and multislice CT (MSCT) are well validated as the reference standard for assessing coronary artery calcification (CAC). Although these CT-based techniques operate on the basis of different imaging platforms, they are considered equivalent in accuracy and reproducibility [10]. EBCT employs a rotating fan of X-rays produced by the impact of a beam of electrons against a tungsten ring; the image acquisition is very rapid and occurs only once per heart beat, toward end diastole; this limits greatly the radiation exposure to the patient. MSCT employs a paired X-ray source detector unit revolving around the patient who lies on a radiological cradle advancing through the revolving beam of X-rays; this newer technology provides a higher radiation dose than EBCT. With MSCT it is possible to obtain 2–320 simultaneous sections according to the brand and model of CT used [11]. With both CT techniques, it is possible to accurately detect and quantify the extent of calcification of the coronary arteries, the aorta and the cardiac valves. Quantification is performed with a score such as the Agatston [12], the volume [13], and the mass method [14]. Although the volume and mass scores are slightly more reproducible and more appropriate for use with modern MSCTs, the Agatston score is the most frequently used and reported method. The Agatston score is calculated as the product of a calcified plaque area by a coefficient related to the peak CT density measured within the same plaque. The sum of all scores of all calcified lesions identified along the coronary tree constitutes the total coronary artery calcium score (CACS). CT imaging cannot clearly differentiate the location of calcium in the intimal or medial layer of the vessel wall. Furthermore, there is only a weak association between CACS and the severity of obstructive coronary artery disease (CAD) [15, 16] (fig. 2).
Braun et al. [17] were the first to utilize EBCT to quantify the extent of CAC in CKD 5D patients. They reported that CACS was much higher in hemodialysis patients compared to healthy individuals as well as patients with known CAD. Similar observations were reported by Goodman et al. [18] in pediatric and young dialysis patients. More recently, investigators showed that progressive decline of renal function is associated with increased prevalence of CAC [19]. The prevalence of CAC in CKD 5D was reported to be as high as 80–85%, while in CKD stages 3–5, CAC is detected in approximately 40–60% of the subjects [20–25]. These findings suggest that CAC tends to progress and increases dramatically after initiation of dialysis.

The presence and severity of CAC has been demonstrated to be a strong predictor of cardiovascular events and death in the general population, while the literature regarding CKD patients is still limited. Matsuoka et al. [26] reported a lower survival in 104 CKD stage 5D patients with CACS greater than the median compared to CACS below the median (p = 0.01). Block et al. [27], in a cohort of 129 incident hemodialysis patients followed prospectively for 44 months, reported that the presence of a baseline CACS >400 was a strong predictor of mortality (HR 4.5, 95% CI 1.33–15.14) after adjustment for age, race, gender and diabetes. In two retrospective analyses, Russo et al. [28] and Shantouf et al. [29] reported a higher risk of all-cause mortality with increasing CACS.

In addition to assessing outcome, several trials have employed serial CT to evaluate the impact of medical interventions on CAC. Four studies compared the impact of two phosphate-binding agents, sevelamer and calcium-based binders, and a very recent one compared the effect of sensipar and vitamin D [20, 29–32]. Most studies showed a difference between interventions, suggesting that CAC may be a valid surrogate marker for research.

There are several limitations to CT-based imaging such as the high equipment cost, the impractical and improbable use for in-office imaging, the required expertise to perform the test and interpret the results, and finally the radiation exposure to the patient. In view of these limitations, other methods to assess and measure VC have been investigated and sometimes compared to CT imaging [27, 33–35]. Though CT angiography has seen a rapid development in recent years, both for the assessment of coronary anatomy and left ventricular function, its application to CKD patients is very limited at the time of this writing, and no recommendation can be given.

Ultrasonography

US-based imaging techniques have been used extensively to evaluate vascular disease in CKD patients. Ultrasonography is very helpful in assessing superficial vessels such as the femoral and carotid arteries. Like planar X-ray, US techniques provide only a qualitative assessment of VC. However, high-resolution US transducers can be used to identify carotid plaques and measure the intima-media thickness of the carotid wall (C-IMT).

C-IMT, a surrogate marker of preclinical atherosclerosis, measures the thickness of both the tunica intima and media of the carotid arteries. C-IMT is increased in the presence of several cardiovascular risk factors such as age, hypertension, hyperlipidemia, diabetes mellitus, inflammation and smoking [36]. CKD has also been reported to be a risk factor for increased C-IMT. Kawamoto et al. [37] evaluated 428 men and 582 women, and reported a significant inverse association between estimated glomerular filtration rate (eGFR) and C-IMT independent of other common cardiovascular risk factors. Several studies also reported an increased C-IMT both in adults and pediatric CKD patients undergoing dialysis as well as renal transplant patients compared with healthy controls [38–40].

The association of C-IMT with an increased risk of events has been clearly established in the general population, but not as well in CKD yet. Benedetto et al. [41] performed sequential carotid echo-Doppler studies in 135 dialysis patients (90 on hemodialysis and 45 on peritoneal dialysis) for a mean follow-up of 15 months. Although the number of plaques increased at a rate of 1 plaque/patient/year and the proportion of patients with severe atherosclerosis (>4 plaques) increased from 25% at baseline to 44% at follow-up (p < 0.001), C-IMT did not change. Moreover, an increase in C-IMT was not predictive of the development of new atherosclerotic plaques and cardiovascular outcome, whereas an increase in number of carotid plaques was a strong predictor of cardiovascular events [HR 1.22 (95% CI 1.05–1.42; p = 0.01) for 1 plaque/year increase].

Unlike dialysis patients, the link between carotid intima-media thickness and cardiovascular disease in CKD stage 3–5 remains to be clarified. In an observational study of 203 Chinese patients (mean age 53.8 ± 10.9 years) in CKD stage 3–4, C-IMT was associated with cardiovascular events [HR, 40.2% (95% CI 2.9–91%; p = 0.03) for each higher quartile of C-IMT], but not with mortality after an average follow-up of 52.4 months [42]. On the other hand, Zoungas et al. [43] reported that C-IMT was not a significant predictor of cardiovascular events after
adjustment for other cardiovascular risk factors in a cohort of 315 patients in CKD stage 4–5.

In some studies, C-IMT has been positively associated [44], and in others it was not associated [38] with CAC; similarly, an association has been found with flow-mediated vasodilatation in some [45] but not in other studies [40, 46]. Finally, a weak association between pulse wave velocity (PWV) and C-IMT has also been described (R = 0.27; p = 0.005) [47].

These results suggest that C-IMT may be associated not only with structural but also with functional abnormalities of the vessel wall and endothelium.

**Echocardiography**

For a long time, echocardiography was the gold standard for assessment of ventricular structure and function as well as valvular function. With the advent of cardiac MR and cardiac CT, some of these functions have been claimed by the more modern techniques. However, the distinct advantages of transthoracic echocardiography, with a compendium of M-mode, two-dimensional (2-D echo) and more recently three-dimensional imaging (3-D echo), are the noninvasive nature of the test, the wide availability of the tool, the moderate cost of the equipment and the ability to assess structural and functional parameters during the same test.

The most frequently evaluated parameters are chamber size, such as left atrial diameter and volume, left ventricular size and mass (LVM), and left ventricular systolic and diastolic function. A known pitfall of echocardiography in CKD is the overestimation of LVM due to volume retention during the interdialytic period. With real-time 3-D echo, accuracy and reproducibility of chamber volume and mass have improved and became comparable to CMR [48]. An enlarged left atrial volume, a surrogate marker of diastolic dysfunction, has been associated with cardiovascular events and mortality [49].

Stress echocardiography has been employed with good results in risk stratification of CAD in CKD. Sensitivity (88%) and specificity (94%) of stress echocardiography for the diagnosis of obstructive CAD is high in CKD patients [50]; furthermore, a positive dobutamine stress echo is highly predictive of major cardiovascular events [51].

Valvular calcification can be assessed only qualitatively, although the mere presence of calcification of one or two valves has been associated with a poor outcome in dialysis patients [52]. Obviously, the hemodynamic significance of valvular disease can be accurately assessed with echocardiography that remains the gold standard for this purpose.

**CMR Imaging**

Cardiovascular magnetic resonance allows an accurate assessment of the structure and function of several cardiovascular structures, and has become an extremely useful clinical and research tool in the general population. However, CMR imaging has seen little utilization in CKD so far.

CMR is the current gold standard to evaluate left ventricular mass, volume and ejection fraction without the need for contrast administration, and is more accurate than 2-D echo [53]. Recently, Moran et al. [54] reported an inverse association between LVH by CMR and cystatin-based eGFR in a sample of 4,971 participants in the Multi-Ethnic Study of Atherosclerosis. As CMR is an accurate volume-independent measurement of cardiac mass in CKD patients, it is emerging as the premiere research tool for evaluating impact of interventions [55–57].

CMR is of great utility in identifying myocardial fibrosis and prior myocardial infarction [58] with delayed gadolinium hyperenhancement. However, gadolinium should be avoided in patients with advanced renal dysfunction (eGFR <30 ml/min/1.75 m²) due to the risk of nephrogenic systemic fibrosis [59].

Finally, CMR is apt to study aortic distensibility and stiffness. Aortic distensibility assessed by CMR was an independent predictor of cardiovascular events and death in 144 CKD stage 5 and 5D patients after 2 years of follow-up [60].

**Functional Methods**

**Myocardial Perfusion Imaging**

Myocardial perfusion imaging (MPI), either single-photon emission CT or positron emission tomography, are the reference standards for the noninvasive assessment of coronary circulatory function (fig. 2). These methods are based on the use of radioactive tracers that are extracted by the myocardium from the circulation. They provide information on global and segmental myocardial perfusion at rest and after stress. The latter is achieved with exercise or pharmacologically with injection of vasodilators (dipyridamole, adenosine or regadenoson) or inodilators (inotropic-vasodilating drugs such as dobutamine). Positron emission tomography also allows the assessment of coronary flow reserve, an index of coronary vasodilator capacity, calculated as the ratio of maximum myocardial blood flow (MBF) during stress to MBF at rest.
Although MPI has traditionally been used to identify perfusion abnormalities due to coronary disease, it has become apparent that perfusion abnormalities may occur in the absence of critical stenoses. In this case, the abnormalities are considered secondary to coronary microcirculatory or endothelial dysfunction.

MPI is frequently performed for risk stratification prior to surgery in renal transplant candidates, although there is no consensus regarding the indication and frequency of performance of this test. Several studies have demonstrated that an abnormal MPI is associated with an unfavorable cardiovascular outcome across all stages of CKD, including incident and prevalent dialysis patients [61–63]. MPI should not be used to screen for CAD in patients with CKD, but is indicated for patients with clinical and electrocardiographic evidence of CAD and patients with advanced CKD stages who underwent an incomplete revascularization [64].

**Assessment of Arterial Elasticity – PWV**

The elastic properties of arteries change with age, advancing stages of diabetes mellitus, hypertension, and CKD [65, 66]. The most notable change is an increase in arterial stiffness that can be measured with methods such as PWV. The test is based on measurement of the velocity of propagation of a pressure wave (forward pressure wave) generated by the ejection of blood from the left ventricle. The wave is reflected at arterial branching points generating reflected waves that travel back toward the left ventricle. The test is noninvasive and requires the detec-

---

**Fig. 2.** Axial CT image of the chest (a) and corresponding myocardial perfusion image of the same hemodialysis patient before and after stress (b). The chest CT image shows extensive calcification (total calcium score = 886) of the left anterior descending coronary artery (LAD), while the nuclear stress test shows normal myocardial perfusion at rest and after stress. AAo = Ascending aorta; DAo = descending aorta; HLA = horizontal long-axis images; SAX = short-axis images; VLA = vertical long-axis images.
tion of a pressure wave at the carotid and the femoral level (i.e. aortic PWV) by means of a tonometer or Doppler probe, timed to the EKG. As arterial stiffness increases, so does the travel velocity of the forward and reflected waves (i.e. PWV increases). The faster return of the reflected waves imposes an increase in afterload (pressure work) on the left ventricle resulting in LVH and reduced coronary perfusion.

Arterial stiffness has been reported to worsen as eGFR declines [67], and there is an association between VC and increased aortic stiffness in CKD patients [22, 34, 47, 68]. Importantly, PWV is a strong predictor of all-cause and cardiovascular mortality in CKD 5D patients [68, 69].

Although PWV has been extensively employed as a research tool, there is no current recommendation for its use in clinical practice. Of interest, preliminary studies have shown that arterial stiffness may be attenuated with medical interventions in CKD patients [57, 70]. Therefore, PWV could become a useful clinical tool in the near future to evaluate the impact of therapeutic interventions in CKD patients.

References


Conclusion

Noninvasive methods for morphological and functional assessment of the cardiovascular system have the potential to improve the care of patients with CKD. Echocardiography is recommended for screening of all patients starting renal replacement therapy [64]. MPI is frequently used to evaluate renal transplant candidates for CAD. Simple tests, such as lateral abdominal radiography and echocardiography, are appropriate alternatives to CT methods to detect vascular and valvular calcification. Surprisingly, despite the fact that VC is highly prevalent and has prognostic implications, screening for it in CKD patients is not recommended [71]. It is the opinion of the authors that this position should be revised in view of the strong positive predictive value of the test as well as the powerful negative predictive value of the absence of cardiovascular calcification. Furthermore, CT remains a useful research tool to determine the effect of various interventions on the progression of VC.

Disclosure Statement

Paolo Raggi received research grants from Genzyme Therapeutics and Amgen.

Coronary-artery calcification in young

C, Gales B, Sider D, Wang Y, Chung J, Emer-

Spiegel DM: Mortality effect of coronary cal-

Kessler PD, Diaz-Buxo JA, Budoff M: A

Kocak H, Gumuslu S, Sahin E, Ceken K, Er-

C, GocmenAY, Yakupoglu G, Ersoy FF, Suleymanglar G, Tuner M: Relationship be-

Zoungas S, Cameron JD, Kerr PG, Wolfe R,

Kawamoto R, Ohtsuka N, Kusunoki T, Yor-

Oh J, Wunsch R, Turzer M, Bahner M, Raggi

Querfeld U, Mehls O, Schaefer F: Ad-

Delucchi A, Dinamarca H, Gainza H, Whitt-

Torrabba I, Igniez G: Carotid intima-

f a r i  A ,  F l o r e s  F ,  G o p a l  A ,  N o o r i  N ,  J i n g  J ,

Muntner P, Block GA: Association of pulse

Muntner P, Block GA, Raggi P: Effects of

Enderle MD, Schroeder S, Ossen R, Meisner

Santos RD, Fachini FC, Carvalho AB, Draibe

Oh J, Wunsch R, Turzer M, Bahner M, Raggi

Kocak H, Gumuslu S, Sahin E, Ceken K, Er-

C, GocmenAY, Yakupoglu G, Ersoy FF, Suleymanglar G, Tuner M: Relationship be-

Zoungas S, Cameron JD, Kerr PG, Wolfe R,

Kocak H, Gumuslu S, Sahin E, Ceken K, Er-

C, GocmenAY, Yakupoglu G, Ersoy FF, Suleymanglar G, Tuner M: Relationship be-

Zoungas S, Cameron JD, Kerr PG, Wolfe R,


Russo CV, Andreucci VE: Pulse pressure and

B, N aso A, N o ss uli K, M o us taf a M , Goo d-

Kovesdy CP, Kalantar-Zadeh K: Total and

f a r i  A ,  F l o r e s  F ,  G o p a l  A ,  N o o r i  N ,  J i n g  J ,

Muntner P, Block GA, Raggi P: Effects of

Enderle MD, Schroeder S, Ossen R, Meisner

Santos RD, Fachini FC, Carvalho AB, Draibe

Oh J, Wunsch R, Turzer M, Bahner M, Raggi

Kocak H, Gumuslu S, Sahin E, Ceken K, Er-

C, GocmenAY, Yakupoglu G, Ersoy FF, Suleymanglar G, Tuner M: Relationship be-

Zoungas S, Cameron JD, Kerr PG, Wolfe R,

Kocak H, Gumuslu S, Sahin E, Ceken K, Er-

C, GocmenAY, Yakupoglu G, Ersoy FF, Suleymanglar G, Tuner M: Relationship be-

Zoungas S, Cameron JD, Kerr PG, Wolfe R,

Kocak H, Gumuslu S, Sahin E, Ceken K, Er-

C, GocmenAY, Yakupoglu G, Ersoy FF, Suleymanglar G, Tuner M: Relationship be-

Zoungas S, Cameron JD, Kerr PG, Wolfe R,
Cardiovascular Imaging in Chronic Kidney Disease

Blood Purif 2011;31:130–137

137